252 related articles for article (PubMed ID: 25617035)
1. Connect MM Registry: The Importance of Establishing Baseline Disease Characteristics.
Rifkin RM; Abonour R; Terebelo H; Shah JJ; Gasparetto C; Hardin J; Srinivasan S; Ricafort R; Nagarwala Y; Durie BG
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):368-76. PubMed ID: 25617035
[TBL] [Abstract][Full Text] [Related]
2. Review of 1027 patients with newly diagnosed multiple myeloma.
Kyle RA; Gertz MA; Witzig TE; Lust JA; Lacy MQ; Dispenzieri A; Fonseca R; Rajkumar SV; Offord JR; Larson DR; Plevak ME; Therneau TM; Greipp PR
Mayo Clin Proc; 2003 Jan; 78(1):21-33. PubMed ID: 12528874
[TBL] [Abstract][Full Text] [Related]
3. Best treatment strategies in high-risk multiple myeloma: navigating a gray area.
Bianchi G; Richardson PG; Anderson KC
J Clin Oncol; 2014 Jul; 32(20):2125-32. PubMed ID: 24888801
[TBL] [Abstract][Full Text] [Related]
4. [The roles of serum free light chain ratio in the diagnosis and prognosis of newly diagnosed multiple myeloma].
Wang PF; Xu Y; Yan S; Yao Y; Zheng HF; Ma L; Jin S; Xu Y; Gong FR; Zhou JZ; Chang HR; Fu CC
Zhonghua Xue Ye Xue Za Zhi; 2016 May; 37(5):377-82. PubMed ID: 27210871
[TBL] [Abstract][Full Text] [Related]
5. Light chain myeloma: A brief report from India.
Singh N; Agrawal N; Sekhri R; Mehta A; Kumar D; Vishwakarma G; Ahmed R; Bhurani D
Indian J Pathol Microbiol; 2019; 62(3):441-444. PubMed ID: 31361235
[TBL] [Abstract][Full Text] [Related]
6. [Biochemical and immunological findings of multiple myeloma].
Asaoku H
Nihon Rinsho; 2007 Dec; 65(12):2256-60. PubMed ID: 18069270
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma.
Kyrtsonis MC; Vassilakopoulos TP; Kafasi N; Sachanas S; Tzenou T; Papadogiannis A; Galanis Z; Kalpadakis C; Dimou M; Kyriakou E; Angelopoulou MK; Dimopoulou MN; Siakantaris MP; Dimitriadou EM; Kokoris SI; Panayiotidis P; Pangalis GA
Br J Haematol; 2007 May; 137(3):240-3. PubMed ID: 17408464
[TBL] [Abstract][Full Text] [Related]
8. Chronic kidney disease stage 5 as the prognostic complement of International Staging System for multiple myeloma.
Hsiao LT; Yang CF; Yang SH; Gau JP; Yu YB; Hong YC; Liu CY; Liu JH; Chen PM; Chiou TJ; Tzeng CH
Eur J Haematol; 2012 Feb; 88(2):159-66. PubMed ID: 21973045
[TBL] [Abstract][Full Text] [Related]
9. Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes.
Shah JJ; Abonour R; Gasparetto C; Hardin JW; Toomey K; Narang M; Srinivasan S; Kitali A; Zafar F; Flick ED; Rifkin RM
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):575-583.e2. PubMed ID: 28886839
[TBL] [Abstract][Full Text] [Related]
10. Bone marrow biopsy in diffuse large B-cell lymphoma: useful or redundant test?
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Acta Oncol; 2015 Jan; 54(1):67-72. PubMed ID: 25263078
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and Management of Multiple Myeloma: A Review.
Cowan AJ; Green DJ; Kwok M; Lee S; Coffey DG; Holmberg LA; Tuazon S; Gopal AK; Libby EN
JAMA; 2022 Feb; 327(5):464-477. PubMed ID: 35103762
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathology Profile and Bone Involvement of Multiple Myeloma Patients in Dharmais National Cancer Hospital, Indonesia.
Sutandyo N; Firna E; Agustina J; Prayogo N; Widjaja L
Asian Pac J Cancer Prev; 2015; 16(15):6261-5. PubMed ID: 26434826
[TBL] [Abstract][Full Text] [Related]
13. Prediction of response and progression in multiple myeloma with serum free light chains assay: corroboration of the serum free light chain response definitions.
Khoriaty R; Hussein MA; Faiman B; Kelly M; Kalaycio M; Baz R
Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):E10-3. PubMed ID: 20223721
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of the international staging system of multiple myeloma and its comparison with the DS and IFM staging system in 122 Chinese patients].
Deng SH; Xu Y; Mai YJ; Wang YF; Zhao YZ; Zou DH; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):217-21. PubMed ID: 18843972
[TBL] [Abstract][Full Text] [Related]
15. Next Generation Sequencing-based Validation of the Revised International Staging System for Multiple Myeloma: An Analysis of the MMRF CoMMpass Study.
Goldsmith SR; Fiala MA; Dukeman J; Ghobadi A; Stockerl-Goldstein K; Schroeder MA; Tomasson M; Wildes TM; Vij R
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):285-289. PubMed ID: 30792096
[TBL] [Abstract][Full Text] [Related]
16. Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease.
Kastritis E; Terpos E; Moulopoulos L; Spyropoulou-Vlachou M; Kanellias N; Eleftherakis-Papaiakovou E; Gkotzamanidou M; Migkou M; Gavriatopoulou M; Roussou M; Tasidou A; Dimopoulos MA
Leukemia; 2013 Apr; 27(4):947-53. PubMed ID: 23183429
[TBL] [Abstract][Full Text] [Related]
17. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
Perosa F; Minoia C; Favoino E; Prete M; Dammacco F
Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035
[TBL] [Abstract][Full Text] [Related]
18. Circulating angiogenic cytokines in multiple myeloma and related disorders.
Urba ska-Rys H; Wierzbowska A; Robak T
Eur Cytokine Netw; 2003; 14(1):40-51. PubMed ID: 12799213
[TBL] [Abstract][Full Text] [Related]
19. Development of a prognostic model for overall survival in multiple myeloma using the Connect
Terebelo HR; Abonour R; Gasparetto CJ; Toomey K; Durie BGM; Hardin JW; Jagannath S; Wagner L; Narang M; Flick ED; Srinivasan S; Yue L; Kitali A; Agarwal A; Rifkin RM;
Br J Haematol; 2019 Dec; 187(5):602-614. PubMed ID: 31382320
[TBL] [Abstract][Full Text] [Related]
20. Factors affecting outcome of patients with multiple myeloma.
Basit A; Siddiqui N; Hameed A; Muzaffar N; Athar S
J Ayub Med Coll Abbottabad; 2014; 26(3):376-9. PubMed ID: 25671952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
